Chemomab Therapeutics Ltd.
Chemomab Therapeutics develops nebokitug, a monoclonal antibody targeting CCL24 for immune-fibrotic diseases.
6-KSep 30Latest SEC filing
Jul 8Latest story
July 2026
Sign inSign inChemomab Therapeutics develops nebokitug, a monoclonal antibody targeting CCL24 for immune-fibrotic diseases.